secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000882095-25-000030
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead Q2: revenue $7.1B, Biktarvy +9%, product sales ex-Veklury +4%; FY guidance raised
--------------------------------------------------------------------------------

- Revenue $7.1B (+2% YoY), product sales ex-Veklury $6.9B (+4%); Biktarvy $3.5B (+9%).
- GAAP diluted EPS $1.56 vs $1.29 YoY; non-GAAP diluted EPS $2.01, flat YoY.
- FY2025 guidance raised: product sales $28.3-28.7B, diluted EPS $5.85-6.15, non-GAAP EPS $7.95-8.25.
- HIV sales +7% to $5.1B; Trodelvy +14% to $364M; Cell therapy -7% to $485M.
- FDA approved Yeztugo as first twice-yearly HIV prevention; MYR impairment $190M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000088209525000030/0000882095-25-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000088209525000030/gild-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000882095-25-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer